Optimization of the Lead Compound NVP-BHG712 as a Colorectal Cancer Inhibitor

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Ephrin type-A receptor 2 (EPHA2) kinase is a receptor tyrosine kinase implicated in cancer and infectious diseases.
• EPHA2 is an under-examined target with significant pharmacological potential.
• Understanding EPHA2's role is crucial for developing targeted therapies.

Purpose of the Study:

• To synthesize and evaluate novel derivatives of NVP-BHG712 and triazine-based compounds as EPHA2 kinase inhibitors.
• To elucidate the binding mode, affinity, and selectivity of these novel inhibitors.
• To assess the efficacy of these compounds in human colon cancer cell lines.

Main Methods:

• Synthesis of EPHA2 inhibitor derivatives.
• X-ray crystallography for binding mode elucidation.
• Microscale thermophoresis for affinity determination.
• Kinobeads assay for selectivity profiling.
• In vitro testing in colon cancer cell lines.

Main Results:

• Eight synthesized inhibitors demonstrated low-nanomolar affinities (K_D <10 nM) for EPHA2.
• Several derivatives showed promising effects in controlling EPHA2-expressing colon cancer cell lines.
• Detailed binding modes and selectivity profiles were established.

Conclusions:

• Novel triazine-based derivatives and NVP-BHG712 analogs are potent EPHA2 inhibitors.
• These compounds represent valuable tools for further research into EPH receptor signaling in cellular contexts.
• The developed inhibitors hold potential for the therapeutic control of human colon carcinoma.